pi4k

CHMFL-PI4K-127 (compound 15g) is a highly selective inhibitor of PfPI4K (Plasmodium falciparum PI4K kinase) with oral activity (IC50=0.9 nM) and exhibits strong inhibitory activity against Plasmodium falciparum 3D7 (EC50=25.1 nM), demonstrating significant anti-malaria effects.

K-Ras G12C-IN-4, is a potent Covalent Inhibitor of KRASG12C..

Antibiotic K 4 is an inhibitor of angiotensin I converting enzyme produced by Actinomadura spiculosospora.

K-Ras ligand-Linker Conjugate 4 is a chemical compound combining a K-Ras recruiting ligand with a PROTAC linker, responsible for recruiting E3 ligases such as VHL, CRBN, MDM2, and IAP. It has the potential to be used in synthesizing PROTAC K-Ras Degrader-1, which shows a degradation efficacy of ≥70% in SW1573 cells[1].

c(phg-isoDGR-(NMe)k) TFA is a potent and selective α5β1-integrin ligand (IC50: 2.9 nM).

PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 value of 3.6 nM.

PI4KIIIbeta-IN-9 is a potent inhibitor of PI4KIIIβ [IC50 of 7 nM].

BF738735 is a selective inhibitor of phosphatidylinositol 4-kinase III beta (PI4KIIIβ, IC50 = 5.7 nM) showing higher activity over α(IC50 = 1.7 μM). BF738735 exhibits a broad spectrum of antiviral activity.

PI4KIII beta inhibitor 3 is a novel, highly effective inhibitor of PI4KIIIβ with an IC50 of 5.7 nM.

PI4KIIIbeta-IN-11 is a PI4KIIIβ inhibitor (mean pIC50=9.1) that can be used to study diseases caused by RNA viruses and Plasmodium falciparum.

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor.

UCB9608 is a selective and orally active PI4KIIIβ inhibitor (IC50: 11 nM), selective over PI3KC2 α, β, and γ lipid kinases.

PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells

PIK-93, the first potent synthetic PI4K inhibitor, exhibits an IC50 of 19 nM and also inhibits PI3Kα with an IC50 of 39 nM.

BRD73842 is an inhibitor of Plasmodium PI4K.

EDI048, also known as compound 1.16, is an orally active inhibitor of Cryptosporidium PI4K, utilized in the study of cryptosporidiosis [1].

MMV024101 is a PI4K inhibitor. MMV024101 exhibits submicromolar potency against P. falciparum NF54 (IC50 =543 nM), low aqueous solubility (<5 μM), and rapid clearance by mouse liver microsomes with only 2% of parent compound remaining after 30 min of incu

GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential.

BQR-695 (NVP-BQR695) is a phosphatidylinositol 4-kinase (PI4K) inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.

T-00127_HEV1 is an inhibitor of phosphatidylinositol 4-kinase III beta (IC50: 60 nM).

UCT943 is an inhibitor of Plasmodium falciparum PI4K (IC50 = 23 nM).

GSK-F1 (PI4KA inhibitor-F1) is a novel potent PI4KA inhibitor.

KDU731 is a promising drug candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety. KDU731is an orally active C. parvum inhibitor of PI4K (IC50: 25 nM). KDU731 blocks Cryptosporidium infection in vitro and in vi

KDU691 is a PI4K inhibitor.

MMV390048 is an antimalarial agent and is a representative of a new chemical class of Plasmodium PI4K inhibitor (Kdapp=0.3 μM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns.